Thrombotic Disorders

Pediatric Clots - Tiny Troubles

• Definition: Pathological formation of blood clots (thrombi) in arteries or veins in children, obstructing blood flow.
• Pediatric vs. Adult Differences:
  • Lower incidence in children.
  • Different risk factor profiles (e.g., congenital heart disease, central lines more prominent in peds).
  • Developmental hemostasis: different levels of coagulation factors.
• Virchow's Triad (Pediatric Context): 📌 SHE
  • Stasis: Immobility, congenital heart disease (CHD) with shunts, Fontan circulation.
  • Hypercoagulability: Sepsis, inherited thrombophilias (e.g., Factor V Leiden, Protein C/S deficiency), nephrotic syndrome, malignancy, certain medications (e.g., L-asparaginase).
  • Endothelial Injury: Central venous lines (CVL), trauma, surgery, vasculitis.

⭐ Central venous lines are a leading risk factor for VTE in hospitalized children.

Clot Catalysts - Why Kids Clot

Pediatric thrombosis often results from an interplay between underlying genetic predispositions and various acquired conditions that promote clot formation.

Inherited Thrombophilias: These are genetic defects increasing thrombosis risk.

Acquired Risk Factors:

• Central Venous Lines (CVL): Most common.
• Sepsis: Systemic inflammation.
• Malignancy: e.g., ALL; L-asparaginase.
• Surgery / Trauma.
• Nephrotic Syndrome: Loses anticoagulants (AT, Protein C/S).
• Antiphospholipid Syndrome (APS).
• Kawasaki Disease: Vasculitis, aneurysms.
• Immobility / Dehydration.

Clot Confirmation - Spotting the Signs

Clinical Presentation (Site-Dependent):

• DVT: Limb swelling, pain, warmth. Neonates: discoloration, edema.
• PE: Sudden dyspnea, chest pain, hypoxia.
• CSVT: Headache, seizures, focal deficits. Neonates: lethargy.
• Arterial: 5 Ps (Pain, Pallor, Pulselessness, Paresthesia, Paralysis); organ ischemia.
• Renal Vein (RVT): Flank mass, hematuria, thrombocytopenia (esp. neonates).

Diagnostic Workup:

• Labs:
  • D-dimer: ↑ (High NPV).
  • Coagulation Profile: PT, aPTT, Fibrinogen.
  • Specific Assays (recurrent/unprovoked): Protein C/S, AT, FVL, Prothrombin G20210A (Timing: ~4-6 weeks post-event, off anticoagulants).
• Imaging:
  • DVT: Doppler US.

    ⭐ Doppler ultrasound is the initial imaging of choice for suspected DVT.

  • PE: CT Pulmonary Angiography (CTPA); V/Q scan.
  • CSVT: MR Venography (MRV) / CT Venography (CTV).
  • Arterial: Doppler US, CTA/MRA.

Clot Combat - Treatment Tactics

• Core Strategy: Anticoagulation to halt clot growth & prevent recurrence.

  Agent	Key Features	Monitoring
  LMWH	Enoxaparin: 1mg/kg BD (>2mo), 1.5mg/kg BD (<2mo). SC.	Anti-Xa levels
  UFH	IV infusion. Rapid onset/offset.	aPTT
  Warfarin	Oral. Target INR 2-3. Bridging needed.	INR
  DOACs	Dabigatran, Rivaroxaban. Oral. Fixed doses. Growing pediatric use.	Minimal/Specific

• Thrombolysis (tPA): For severe, life/limb-threatening clots. High bleeding risk.
• Prophylaxis: Crucial for high-risk (central lines, surgery, inherited thrombophilia).
• Special Scenarios:
  • Neonatal Thrombosis: Often catheter-related. LMWH is first-line.
  • Purpura Fulminans: Urgent anticoagulation (LMWH/UFH), FFP, Protein C.

⭐ LMWH is generally preferred for anticoagulation in children due to predictable pharmacokinetics and subcutaneous administration.

High‑Yield Points - ⚡ Biggest Takeaways

• Factor V Leiden is the most common inherited thrombophilia; central venous lines are a key acquired risk.
• Neonatal thrombosis is often linked to umbilical catheters or maternal conditions like Antiphospholipid Syndrome (APS).
• Severe Protein C or S deficiency can present as neonatal purpura fulminans.
• Kawasaki disease poses a risk for coronary artery thrombosis from aneurysms.
• Low Molecular Weight Heparin (LMWH) is the preferred initial anticoagulant in most pediatric thrombotic events.
• Nephrotic syndrome is a significant acquired risk factor due to urinary loss of anticoagulant proteins.
• Always investigate for underlying malignancy or sepsis in unexplained pediatric thrombosis.